Business Wire India

Takeda Pharmaceutical Company Limited announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.

The LooK SPOT solution is an intelligent and innovative way to deploy technologies to better protect the health of people across the region. Being able to have a quick and accurate COVID-19 diagnosis can interrupt transmission, aid clinical management, and help proper allocation of resources to isolation.

Smiths Detection, a global leader in threat detection and security screening technologies, reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

XECH, India’s emerging innovator brand, has launched XECH STEROSTET – one-of-its-kind and India’s first Stethoscope Sterilizer which uses a special UV-C GI Technology to effectively sterilize stethoscopes diaphragms of all sizes up to 99.9999%.

Takeda Pharmaceutical Company Limited announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel (development code: Cx601) for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease (CD).

Rhizen Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company, announced that its novel next generation PI3K-delta inhibitor, Umbralisib, which was licensed to TG Therapeutics has secured USFDA accelerated approval for the treatment of : (1) adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen, and (2) adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

Mundipharma and Cidara Therapeutics announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rezafungin, a novel, once-weekly echinocandin, for the treatment of invasive candidiasis (IC).